<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>References</title>
</head>
<body>

<table>
    <tr>
        <td>
            1)
        </td>
        <td>
            <a href="https://nomuraresearchgroup.com/research/">Nomura2020</a>
        </td>
        <td>
            Nomura, D. K.<br>
            "Our Research."<br>
            <i>Nomura Research Group Website</i>, <b>2020</b>.<br>
        </td>
    </tr>
    <tr>
        <td>
            2)
        </td>
        <td>
            <a href="https://doi.org/10.1016/j.chembiol.2010.05.011">Crews2010</a>
        </td>
        <td>
            Crews, C. M.
            Targeting the Undruggable Proteome: The Small Molecules of My Dreams
            Chemistry & Biology, Elsevier BV, 2010, 17, 551-555
        </td>
    </tr>
    <tr>
        <td>
            3)
        </td>
        <td>
            <a href="https://www.sigmaaldrich.com/technical-documents/articles/technology-spotlights/ligandability.html">MS2020</a>
        </td>
        <td>
            Millipore-Sigma
            Proteomic Ligandability Assessment
            Merck KGaA, Darmstadt, Germany, 2020
        </td>
    </tr>
    <tr>
        <td>
            4)
        </td>
        <td>
            <a href="https://doi.org/10.1016/j.copbio.2016.08.003">Roberts2017</a>
        </td>
        <td>
            Roberts, A. M.; Ward, C. C. & Nomura, D. K.
            Activity-based protein profiling for mapping and pharmacologically interrogating proteome-wide ligandable hotspots
            Current Opinion in Biotechnology, Elsevier BV, 2017, 43, 25-33
        </td>
    </tr>
    <tr>
        <td>
            5)
        </td>
        <td>
            <a href="https://doi.org/10.1146/annurev-biochem-060713-035708">Niphakis2014</a>
        </td>
        <td>
            Niphakis, M. J. & Cravatt, B. F.<br>
            "Enzyme Inhibitor Discovery by Activity-Based Protein Profiling."<br>
            Annual Review of Biochemistry, Annual Reviews, 2014, 83, 341-377.
        </td>
    </tr>
    <tr>
        <td>
            6)
        </td>
        <td>
            <a href="https://doi.org/10.1002/9783527677047.ch03">Bauer2016</a>
        </td>
        <td>
            Bauer, U. & Breeze, A. L.<br>
            "'Ligandability' of Drug Targets: Assessment of Chemical Tractability via Experimental and In Silico Approaches."<br>
            <i>Wiley</i>, <b>2016</b>, 35-62.
        </td>
    </tr>
    <tr>
        <td>
            7)
        </td>
        <td>
            <a href="https://doi.org/10.1038/nature18002">Backus2016</a>
        </td>
        <td>
            Backus, K. M.; Correia, B. E.; Lum, K. M.; Forli, S.; Horning, B. D.; González-Páez, G. E.; Chatterjee,
            S.; Lanning, B. R.; Teijaro, J. R.; Olson, A. J.; Wolan, D. W. & Cravatt, B. F.<br>
            "Proteome-wide covalent ligand discovery in native biological systems."<br>
            Nature, Springer Science and Business Media LLC, 2016, 534, 570-574.
        </td>
    </tr>
    <tr>
        <td>
            8)
        </td>
        <td>
            <a href="https://doi.org/10.1038/s41586-020-2223-y">Jin2020</a>
        </td>
        <td>
            Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Peng, C.; Duan, Y.;
            Yu, J.; Wang, L.; Yang, K.; Liu, F.; Jiang, R.; Yang, X.; You, T.; Liu, X.; Yang, X.; Bai, F.; Liu, H.;
            Liu, X.; Guddat, L. W.; Xu, W.; Xiao, G.; Qin, C.; Shi, Z.; Jiang, H.; Rao, Z. & Yang, H.<br>
            "Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors."<br>
            Nature, Springer Science and Business Media LLC, 2020, 582, 289-293.
        </td>
    </tr>
    <tr>
        <td>
            9)
        </td>
        <td>
            <a href="https://doi.org/10.1021/acs.jmedchem.5b01461">Pillaiyar2016</a>
        </td>
        <td>
            Pillaiyar, T.; Manickam, M.; Namasivayam, V.; Hayashi, Y. & Jung, S.-H.<br>
            "An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors:
            Peptidomimetics and Small Molecule Chemotherapy."<br>
            <i>Journal of Medicinal Chemistry, American Chemical Society (ACS)</i>, <b>2016</b>, <i>5</i>, 6595-6628.
        </td>
    </tr>
    <tr>
        <td>
            10)
        </td>
        <td>
            <a href="https://doi.org/10.1074/jbc.M310875200">Fan2003</a>
        </td>
        <td>
            Fan, K.; Wei, P.; Feng, Q.; Chen, S.; Huang, C.; Ma, L.; Lai, B.; Pei, J.; Liu, Y.; Chen, J. & Lai, L.
        Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase
        Journal of Biological Chemistry, American Society for Biochemistry & Molecular Biology (ASBMB), 2003, 279, 1637-1642
        </td>
    </tr>
    <tr>
        <td>
            11)
        </td>
        <td>
            <a href="https://doi.org/10.1039/C8CC01485J">Hoch2018</a>
        </td>
        <td>
            Hoch, D. G.; Abegg, D. & Adibekian, A.<br>
          "Cysteine-reactive probes and their use in chemical proteomics."<br>
          <i>Chemical Communications, Royal Society of Chemistry (RSC)</i>, <b>2018</b>, <i>54</i>, 4501-4512.
        </td>
    </tr>
    <tr>
        <td>
            12)
        </td>
        <td>
            <a href="">Nomura_2020</a>
        </td>
        <td>
            Nomura, D. K.
            Discovering Coronavirus Main Protease Inhibitors (Unpublished)
            2020
        </td>
    </tr>
    <tr>
      <td>
            13)
      </td>
      <td>
          <a href="https://doi.org/10.1038/s41586-019-1103-9">Behan2019</a>
      </td>
      <td>
          Behan, F. M.; Iorio, F.; Picco, G.; Gonçalves, E.; Beaver, C. M.; Migliardi, G.; Santos, R.; Rao, Y.;
          Sassi, F.; Pinnelli, M.; Ansari, R.; Harper, S.; Jackson, D. A.; McRae, R.; Pooley, R.; Wilkinson, P.;
          van der Meer, D.; Dow, D.; Buser-Doepner, C.; Bertotti, A.; Trusolino, L.; Stronach, E. A.;
          Saez-Rodriguez, J.; Yusa, K. & Garnett, M. J.<br>
          "Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens."<br>
          <i>Nature, Springer Science and Business Media LLC</i>, <b>2019</b>, <i>568</i>, 511-516.
      </td>
  </tr>
    <tr>
      <td>
            14)
      </td>
      <td>
          <a href="https://doi.org/10.1038/s41586-019-1103-9">Behan2019</a>
      </td>
      <td>
          Behan, F. M.; Iorio, F.; Picco, G.; Gonçalves, E.; Beaver, C. M.; Migliardi, G.; Santos, R.; Rao, Y.;
          Sassi, F.; Pinnelli, M.; Ansari, R.; Harper, S.; Jackson, D. A.; McRae, R.; Pooley, R.; Wilkinson, P.;
          van der Meer, D.; Dow, D.; Buser-Doepner, C.; Bertotti, A.; Trusolino, L.; Stronach, E. A.;
          Saez-Rodriguez, J.; Yusa, K. & Garnett, M. J.<br>
          "Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens."<br>
          <i>Nature, Springer Science and Business Media LLC</i>, <b>2019</b>, <i>568</i>, 511-516.
      </td>
  </tr>
    <tr>
        <td>
            15)
        </td>
        <td>
            <a href="https://doi.org/10.1146/annurev-pharmtox-010715-103440">Lazo2016</a>
        </td>
        <td>
            Lazo, J. S. & Sharlow, E. R.
            Drugging Undruggable Molecular Cancer Targets
            Annual Review of Pharmacology and Toxicology, Annual Reviews, 2016, 56, 23-40
        </td>
    </tr>
    <tr>
        <td>
            16)
        </td>
        <td>
            <a href="https://doi.org/10.1158/1078-0432.ccr-07-2184">Verdine2007</a>
        </td>
        <td>
            <h3>The Challenge of Drugging Undruggable Targets in Cancer: Lessons Learned from Targeting BCL-2 Family Members</h3>
            Verdine, G. L. & Walensky, L. D.
            Clinical Cancer Research, American Association for Cancer Research (AACR), 2007, 13, 7264-7270
        </td>
    </tr>


    <tr>
        <td>
            17)
        </td>
        <td>
            <a href="">Koehler2010</a>
        </td>
        <td>
            Koehler, A. N.<br>
            "A complex task? Direct modulation of transcription factors with small molecules."<br>
            Current Opinion in Chemical Biology, Elsevier BV, 2010, 14, 331-340.
        </td>
    </tr>
    <tr>
        <td>
            18)
        </td>
        <td>
            <a href="">Bushweller2019</a>
        </td>
        <td>
            Bushweller, J. H.<br>
            "Targeting transcription factors in cancer — from undruggable to reality."<br>
            Nature Reviews Cancer, Springer Science and Business Media LLC, 2019, 19, 611-624.
        </td>
    </tr>
  <tr>
    <td>
        19)
    </td>
    <td>
        <a href="https://doi.org/10.1021/acschembio.8b01083">Ward2019</a>
    </td>
    <td>
        Ward, C. C.; Kleinman, J. I.; Brittain, S. M.; Lee, P. S.; Chung, C. Y. S.; Kim, K.; Petri, Y.; Thomas, J. R.;
        Tallarico, J. A.; McKenna, J. M.; Schirle, M. & Nomura, D. K.<br>
        "Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications."<br>
        <i>ACS Chemical Biology, American Chemical Society (ACS)</i>, <b>2019</b>, <i>14</i>, 2430-2440.
    </td>
  </tr>


</table>
</body>
</html>